Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.3.1233

A Systematic Review of Risk Factors for Brain Metastases and Value of Prophylactic Cranial Irradiation in Non-Small Cell Lung Cancer  

Sun, Dian-Shui (Cancer Center, the Second Hospital of Shandong University)
Hu, Li-Kuan (Cancer Center, Qilu Hospital of Shandong University)
Cai, Ying (Medical Department, Affiliated Hospital of Shandong University of Traditional Chinese Medicine)
Li, Xiao-Mei (Cancer Center, the Second Hospital of Shandong University)
Ye, Lan (Cancer Center, the Second Hospital of Shandong University)
Hou, Hua-Ying (Cancer Center, the Second Hospital of Shandong University)
Wang, Cui-Hong (Cancer Center, the Second Hospital of Shandong University)
Jiang, Yu-Hua (Cancer Center, the Second Hospital of Shandong University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.3, 2014 , pp. 1233-1239 More about this Journal
Abstract
Background: The incidence of brain metastases (BM) varies in patients with non-small cell lung cancer (NSCLC), calls into question the value of prophylactic cranial irradiation (PCI). It is possible that clinicopathologic characteristics are associated with the development of BM, but these have yet to be identified in detail. Thus, we conducted the present meta-analysis on risk factors for BM and the value of PCI in patients with NSCLC. Methods: Eligible data were extracted and the risk factors for BM and the value of PCI in patients with NSCLC were analyzed by calculating the pooled odds ratio (OR). Heterogeneity was detected using Q and I-squared statistics, and publication bias was tested by funnel plots and Egger's test. Results: Six randomized controlled trials with a focus on the value of PCI and 13 eligible studies with a focus on risk factors for BM were included. PCI significantly reduced the incidence of BM in patients with NSCLC (p=0.000, pooled OR=0.34, 95% confidence interval = 0.37-0.59). Compared with non-squamous cell carcinoma, squamous cell carcinoma was associated with a low incidence of BM in patients with NSCLC (p=0.000, pooled OR=0.47, 95% confidence interval =0.34-0.65). The funnel plot and Egger's test suggested that there was no publication bias in the current meta-analysis. Conclusions: This meta-analysis provides statistical evidence that compared with non-squamous cell carcinoma, squamous cell carcinoma can be used as a predictor for BM in patients with NSCLC, and PCI might reduce the incidence of BM in patients with NSCLC, but does not provide a survival benefit.
Keywords
Meta-analysis; risk factors; brain metastases; prophylactic cranial irradiation; NSCLC;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Albain KS, Rusch VW, Crowley JJ, et al (1995). Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer:mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol, 13, 1880-92.
2 Wang SY, Ye X, Ou W, et al (2009). Risk of cerebral metastases for postoperative locally advanced non-small-cell lung cancer. Lung Cancer, 64, 238-43.   DOI   ScienceOn
3 Russell AH, Pajak TE, Selim HM, et al (1991). Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Rad Onc Biol Phys, 21, 637-43.   DOI
4 Umsawasdi T, Valdivieso M, Chen TT, et al (1984). Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol, 2, 253-9.
5 Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al (1993). Treatment of single brain metastases: Radiotherapy alone or combined with neurosurgery? Ann Neurol, 33, 583-90.   DOI   ScienceOn
6 Zeng YD, Zhang L, Liao H, et al (2012). Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study. Asian Pac J Cancer Prev, 13, 909-14.   과학기술학회마을   DOI   ScienceOn
7 Zhao J, Chen M, Zhong W, et al (2012). Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin Lung Cancer, 14, 188-93.
8 Pan M, Santamaria M, Wollman DB (2007). CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nat Clin Pract Oncol, 4, 603-7.   DOI   ScienceOn
9 Lester JF, MacBeth FR, Coles B (2005). Prophylactic cranial irradiation for preventing brain metastases in patients undergoing radical treatment for non-small-cell lung cancer: a Cochrane Review. Int J Radiat Oncol Biol Phys, 63, 690-4.   DOI   ScienceOn
10 Mamon HJ, Yeap BY, Janne PA, et al (2005). High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol, 23, 1530-7.   DOI   ScienceOn
11 Miller TP, Crowley JJ. Mira J, et al (1998). A randomized trial of chemotherapy and radiotherapy for stage III non-small cell lung cancer. Cancer Therapeutics, 4, 229 -36.
12 Patchell RA, Tibbs PA, Walsh JW, et al (1990). A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med, 322, 494-500.   DOI   ScienceOn
13 Petrovic M, Ilic N, Loncarevic O, et al (2011). Risk factors for brain metastases in surgically staged IIIA non-small cell lung cancer patients treated with surgery, radiotherapy and chemotherapy. Vojnosanit Pregl, 68, 643-9.   DOI
14 Ding X, Dai H, Hui Z, et al (2012). Risk factors of brain metastases in completely resected pathological stage IIIA-N2 non-small cell lung cancer. Radiat Oncol, 7, 119.   DOI
15 Pottgen C, Eberhardt W, Grannass A, et al (2007). Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol, 25, 4987-92.   DOI   ScienceOn
16 Robnett TJ, Machtay M, Stevenson JP, et al (2001). Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol, 19, 1344-9.
17 Gore EM, Bae K, Wong SJ, et al (2011). Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol, 29, 272-8.   DOI   ScienceOn
18 Gaspar L, Scott C, Rotman M, et al (1997). Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys, 37, 745-51.   DOI   ScienceOn
19 Gore E (2006). Prophylactic cranial irradiation versus observation in stage III non-small-cell lung cancer. Clin Lung Cancer, 7, 276-8.   DOI   ScienceOn
20 Horinouchi H, Sekine I, Sumi M, et al (2012). Brain metastases after definitive concurrent chemoradiotherapy in patients with stage III lung adenocarcinoma: carcinoembryonic antigen as a potential predictive factor. Cancer Sci, 103, 756-9.   DOI   ScienceOn
21 Hubbs JL, Boyd JA, Hollis D, et al (2010). Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. Cancer, 116, 5038-46.   DOI   ScienceOn
22 Andre F, Grunenwald D, Pujol JL, et al (2001). Patterns of relapse of N2 non-small-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer, 91, 2394-400.   DOI
23 Keith B, Vincent M, Stitt L, et al (2002). Subsets more likely to benefit from surgery or prophylactic cranial irradiation after chemoradiation for localized non-small-cell lung cancer. Am J Clin Oncol, 25, 583-7.   DOI   ScienceOn
24 Lee DS, Kim YS, Jung SL, et al (2012). The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer. Tumour Biol, 33, 1065-73.   DOI   ScienceOn
25 Bajard A, Westeel V, Dubiez A, et al (2004). Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer, 45, 317-23.   DOI   ScienceOn
26 Arrieta O, Saavedra-Perez D, Kuri R, et al (2009). Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis. BMC Cancer, 22, 119.
27 Auperin A, Arriagada R, Pignon JP, et al (1999). Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med, 341, 476-84.   DOI   ScienceOn
28 Ceresoli GL, Cappuzzo F, Gregorc V, et al (2004). Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol, 15, 1042-7.   DOI   ScienceOn
29 Ceresoli GL, Reni M, Chiesa G, et al (2002). Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer, 95, 605-12.   DOI   ScienceOn
30 Chen AM, Jahan TM, Jablons DM, et al (2007). Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced nonsmall-cell lung cancer: clinical implications for the subsequent management of the brain. Cancer, 109, 1668-75.   DOI   ScienceOn
31 Cox JD, Stanley K, Petrovich Z, et al (1981). Cranial irradiation in cancer of the lung of all cell types. JAMA, 245, 469-72.   DOI   ScienceOn
32 Dimitropoulos C, Hillas G, Nikolakopoulou S, et al (2011). Prophylactic cranial irradiation in non-small cell lung cancer patients: who might be the candidates?. Cancer Manag Res, 3, 287-94.